Cargando…
Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
The high prices of innovative medicines endanger access to care worldwide. Sustainable prices need to be affordable while sufficiently incentivizing research and development (R&D) investments. A proposed solution is increased transparency. Proponents argue that price and R&D cost confidentia...
Autores principales: | Franzen, Nora, Ziegler, Andreas, Romagnoli, Giorgia, Retèl, Valesca P., Offerman, Theo J.S., van Harten, Wim H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973423/ https://www.ncbi.nlm.nih.gov/pubmed/36860697 http://dx.doi.org/10.1158/2767-9764.CRC-21-0031 |
Ejemplares similares
-
Can Price Transparency Contribute to More Affordable Patient Access to Medicines?
por: Vogler, Sabine, et al.
Publicado: (2017) -
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022) -
Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016) -
Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022) -
Price, availability and affordability of medicines
por: Mhlanga, Brenda S., et al.
Publicado: (2014)